Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

An inactivated cell-culture vaccine against yellow fever.

Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, Trent DW.

N Engl J Med. 2011 Apr 7;364(14):1326-33. doi: 10.1056/NEJMoa1009303.

2.

Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults.

Silva ML, Martins MA, Espírito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JG, Homma A, Kroon EG, Teixeira-Carvalho A, Elói-Santos SM, Martins-Filho OA.

Vaccine. 2011 Jan 10;29(3):583-92. doi: 10.1016/j.vaccine.2010.08.046. Epub 2010 Aug 21.

PMID:
20732465
3.

Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Staples JE, Gershman M, Fischer M; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 Jul 30;59(RR-7):1-27.

4.

Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.

Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW.

Vaccine. 2010 May 14;28(22):3827-40. doi: 10.1016/j.vaccine.2010.03.023. Epub 2010 Mar 26.

PMID:
20347059
5.

Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy.

Roukens AH, Vossen AC, van Dissel JT, Visser LG.

Vaccine. 2009 Apr 21;27(18):2408-9. doi: 10.1016/j.vaccine.2009.02.049. Epub 2009 Feb 24.

PMID:
19368780
6.

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.

Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, Bae HG, Litzba N, Staub T, Hatz C, Furrer H; Swiss HIV Cohort Study.

Clin Infect Dis. 2009 Mar 1;48(5):659-66. doi: 10.1086/597006.

7.

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.

Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B.

Nat Immunol. 2009 Jan;10(1):116-25. doi: 10.1038/ni.1688. Epub 2008 Nov 23.

8.

Adverse event reports following yellow fever vaccination.

Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB.

Vaccine. 2008 Nov 11;26(48):6077-82. doi: 10.1016/j.vaccine.2008.09.009. Epub 2008 Sep 20.

PMID:
18809449
9.

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, Glidewell J, Monson N, Zhu T, Zhu H, Staprans S, Lee D, Brinton MA, Perelygin AA, Vellozzi C, Brachman P Jr, Lalor S, Teuwen D, Eidex RB, Cetron M, Priddy F, del Rio C, Altman J, Ahmed R.

J Infect Dis. 2008 Aug 15;198(4):500-7. doi: 10.1086/590187.

10.

International laboratory network for yellow fever vaccine-associated adverse events.

Barrett AD, Niedrig M, Teuwen DE.

Vaccine. 2008 Oct 9;26(43):5441-2. doi: 10.1016/j.vaccine.2008.06.025. Epub 2008 Jun 30. No abstract available.

PMID:
18590790
11.

Biology of immune responses to vaccines in elderly persons.

Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B.

Clin Infect Dis. 2008 Apr 1;46(7):1078-84. doi: 10.1086/529197. Review.

12.

Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.

Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG.

PLoS One. 2008 Apr 23;3(4):e1993. doi: 10.1371/journal.pone.0001993.

13.

Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic.

Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H, McDermott DH, Murphy PM.

J Infect Dis. 2008 Jan 15;197(2):262-5. doi: 10.1086/524691.

14.

Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.

Belsher JL, Gay P, Brinton M, DellaValla J, Ridenour R, Lanciotti R, Perelygin A, Zaki S, Paddock C, Querec T, Zhu T, Pulendran B, Eidex RB, Hayes E.

Vaccine. 2007 Dec 5;25(50):8480-5. Epub 2007 Sep 18.

PMID:
18023511
15.

Acute viscerotropic disease following vaccination against yellow fever.

Hayes EB.

Trans R Soc Trop Med Hyg. 2007 Oct;101(10):967-71. Epub 2007 Jul 31. Review.

PMID:
17669451
16.

Immunity and ageing in man.

Pawelec G.

Exp Gerontol. 2006 Dec;41(12):1239-42. Epub 2006 Nov 21. Review.

PMID:
17118601
17.

Yellow fever 17D vaccine safety and immunogenicity in the elderly.

Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, Bedford P.

Hum Vaccin. 2005 Sep-Oct;1(5):207-14. Epub 2005 Sep 2.

PMID:
17012867
18.

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

Doblas A, Domingo C, Bae HG, Bohórquez CL, de Ory F, Niedrig M, Mora D, Carrasco FJ, Tenorio A.

J Clin Virol. 2006 Jun;36(2):156-8. Epub 2006 Apr 4.

PMID:
16597510
19.

Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].

Martins RM, Galler R, Freire MS, Camacho LA, de Lourdes S Maia M, Homma A.

Vaccine. 2007 Jan 2;25(1):10-1. Epub 2006 Jan 18.

PMID:
16448728
20.

[Adverse effects of attenuated yellow fever vaccine with multiple organ injury--a case report].

Zhou Q, Liu DW, Shi Y, Long Y, Li DJ, Liu HZ, Wang H, Ni X, Cai WS, Wang AX.

Zhonghua Yi Xue Za Zhi. 2005 Apr 6;85(13):936. Chinese. No abstract available.

PMID:
16029537
Items per page

Supplemental Content

Write to the Help Desk